Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor
Naporafenib是一种潜在的首创和最佳的全RAF抑制剂
Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses
Erasca还在进行中的SEACRAFt-2关键3期试验中评估了naporafenib和trametinib的联合应用，在此前的NRAS突变黑色素瘤合并分析中已经显示出有利的生存
Erasca to host virtual R&D update for investors on Thursday, October 24, 2024, at 8:30 AM ET
Erasca将于2024年10月24日星期四美国东部时间上午8:30举行虚拟投资者研发更新会议
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.
圣地亚哥，2024年9月25日（环球社会新闻通讯社）-- Erasca公司（纳斯达克：ERAS），一家专注于发现、开发和商业化RAS/MAPk通路驱动癌症患者的疗法的临床阶段精准肿瘤学公司，今天宣布了在第36届EORTC-NCI-AACR（ENA）分子靶向与癌症治疗研讨会上展示naporafenib和trametinib（MEKINIST）联合用于具有RAS Q61X突变的局部晚期不可切除或转移固体肿瘤恶性肿瘤患者的初步SEACRAFt-1 1期数据的口头报告。会议将于10月23日至25日在西班牙巴塞罗那举行。Naporafenib是一种潜在的首创和最佳的全RAF抑制剂。
Erasca plans to host a virtual investor event to provide a research and development (R&D) update on naporafenib and the RAS targeting franchise on Thursday, October 24, 2024, at 8:30 AM ET in conjunction with the 36th ENA Symposium. A live question and answer session will follow the formal presentation. To register for the event, please click here.
Erasca计划举办虚拟投资者活动，就naporafenib和RAS靶向特许权进行研究与开发更新，在与第36届ENA研讨会同时于2024年10月24日星期四美国东部时间上午8:30举行。正式演示之后将进行现场问答环节。要注册参加此活动，请单击此处。
